|NASDAQ: CORT||Healthcare / Biotechnology / USA|
|21.77||+0.6600||+3.13%||Vol 693.19K||1Y Perf -12.48%|
|Mar 24th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||31.50||Analyst Rating||Moderate Buy 2.17|
|Potential %||44.69||Finscreener Ranking||★★★★+ 57.46|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★+ 61.29|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 81.58|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||35.37||Earnings Rating||Strong Sell|
|Market Cap||2.35B||Earnings Date||4th May 2023|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th May 2023|
|Estimated EPS Next Report||0.23|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.06M|
|Avg. Monthly Volume||988.86K|
|Avg. Quarterly Volume||711.78K|
Corcept Therapeutics Incorporated (NASDAQ: CORT) stock closed at 21.77 per share at the end of the most recent trading day (a 3.13% change compared to the prior day closing price) with a volume of 693.19K shares and market capitalization of 2.35B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 236 people. Corcept Therapeutics Incorporated CEO is Joseph K. Belanoff.
The one-year performance of Corcept Therapeutics Incorporated stock is -12.48%, while year-to-date (YTD) performance is 7.19%. CORT stock has a five-year performance of 30.36%. Its 52-week range is between 17.19 and 30.14, which gives CORT stock a 52-week price range ratio of 35.37%
Corcept Therapeutics Incorporated currently has a PE ratio of 20.60, a price-to-book (PB) ratio of 4.69, a price-to-sale (PS) ratio of 7.39, a price to cashflow ratio of 17.80, a PEG ratio of 2.32, a ROA of 22.70%, a ROC of 22.65% and a ROE of 25.09%. The company’s profit margin is 28.39%, its EBITDA margin is 32.60%, and its revenue ttm is $298.80 Million , which makes it $2.78 revenue per share.
Of the last four earnings reports from Corcept Therapeutics Incorporated, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $0.23 for the next earnings report. Corcept Therapeutics Incorporated’s next earnings report date is 04th May 2023.
The consensus rating of Wall Street analysts for Corcept Therapeutics Incorporated is Moderate Buy (2.17), with a target price of $31.5, which is +44.69% compared to the current price. The earnings rating for Corcept Therapeutics Incorporated stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Corcept Therapeutics Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Corcept Therapeutics Incorporated has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.47, ATR14 : 0.69, CCI20 : 125.68, Chaikin Money Flow : -0.10, MACD : -0.19, Money Flow Index : 39.05, ROC : 3.62, RSI : 54.92, STOCH (14,3) : 99.25, STOCH RSI : 1.00, UO : 55.59, Williams %R : -0.75), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Corcept Therapeutics Incorporated in the last 12-months were: Daniel N. Swisher (Option Excercise at a value of $131 000), Daniel N. Swisher (Sold 15 385 shares of value $435 703 ), David L. Mahoney (Option Excercise at a value of $121 500), G. Charles Robb (Option Excercise at a value of $416 000), G. Charles Robb (Sold 158 401 shares of value $3 902 334 ), Hazel Hunt (Option Excercise at a value of $104 000), James N. Wilson (Option Excercise at a value of $624 000), Joseph K. Belanoff (Option Excercise at a value of $1 664 000), Joseph K. Belanoff (Sold 335 019 shares of value $8 798 951 ), Sean Maduck (Option Excercise at a value of $-309 604), Sean Maduck (Sold 100 825 shares of value $2 632 040 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Moderate Buy||Moderate Buy||Moderate Buy|
Corcept Therapeutics Inc is engaged in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.
CEO: Joseph K. Belanoff
Telephone: +1 650 327-3270
Address: 149 Commonwealth Drive, Menlo Park 94025, CA, US
Number of employees: 236
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.